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Two important preanalytical protocols performed on liquid-based cytological specimens, namely, automated cytology process-
ing and glacial acetic acid (GAA) treatment, may occur prior to the arrival of specimens in a molecular diagnostics laboratory.
Ninety-two ThinPrep vials previously positive for high-risk human papillomavirus (HPV) via the Cervista HPVHR test were
preselected and alternated with 92 previously negative ThinPrep vials. The specimen set was processed in a consecutive fashion
by an automated cytology processor without fastidious decontamination precautions. Carryover potential was subsequently
assessed by performance of the Aptima HPV assay on aliquots from reprocessed ThinPrep vials. All previously negative Thin-
Prep vials yielded a negative result following routine automated cytology processing, despite close proximity to known-positive
ThinPrep vials. In separate experiments, aliquots from 236 ThinPrep vials were forwarded for tandem analysis with and without
GAA treatment. Data fromGAA- andmock-treated specimens generated by Aptima HPVwere compared to correlate data gener-
ated by Cervista. A 99.2% concordance of Aptima HPV results fromGAA-treated andmock-treated specimens was noted. This
result differed from the concordance result derived from Cervista (91.5%; P< 0.0002). Of the initially positive Cervista results,
21.9% reverted to negative following GAA treatment; the correlate value was 2.7% for Aptima HPV (P 0.01). While deleterious
effects of GAA treatment on genomic DNAwere noted with Cervista (P 0.0015), GAA treatment had no significant effects on
Aptima HPV specimen signal/cutoff ratios or amplification of internal control RNA (P> 0.07). The validity of an Aptima HPV
result is independent of GAA treatment and routine automated cytology processing.
Detection of high-risk human papillomavirus (HPV) E6/E7transcripts is a recent diagnostic advancement in the context
of cervical cancer triage. Transcription-mediated amplification
(TMA) of these targets (Aptima HPV; Hologic/Gen-Probe, San
Diego, CA) performs in an equivalent fashion to high-risk HPV
DNAhybridization assays, such as theDigeneHC2 high-riskHPV
DNA test (Qiagen, Gaithersburg, MD) (1–4) and the Cervista
HPV HR (Cervista; Hologic, Madison, WI) (5), for the detection
of indolent cervical intraepithelial neoplasia (CIN) 2. The afore-
mentioned studies also document improved specificity of Aptima
HPV over that of DNA hybridization in the context of atypical
squamous cells of undetermined significance (ASC-US) or non-
significant cytology diagnoses and in cases of non-CIN 2 biopsy
results.
AptimaHPV is an FDA-cleared assay for the analysis of liquid-
based cytology collections (ThinPrep; Hologic, Marlborough,
MA) on high-throughput instrumentation such as the Tigris DTS
system (6). Past package insert guidelines have referred to metic-
ulous and costly cross-contamination mitigation steps required
when the ThinPrep vials are subjected to automated cytology pro-
cessing prior to HPV detection (7). In addition, specimen carry-
over (potentiated by either form of automation) may be of con-
cern to both laboratorians and cytopathologists. Moreover,
previous data (8–10) suggest that performance characteristics of
DNA-based HPVmodalities may be affected by glacial acetic acid
(GAA) treatment of liquid-based cytology collections. The pur-
pose of this investigationwas to assess such preanalytical concerns
inherent to the performance of the Aptima HPV.
(Results of this work were previously presented, in part, at the
113th GeneralMeeting of the American Society forMicrobiology,
Denver, CO, 18 to 21 May, 2013.)
MATERIALS AND METHODS
Cytology specimens. In a study approved by the Wheaton Franciscan
Healthcare Institutional Review Board, residual fluid fromThinPrep vials
was subjected to molecular analysis. A ThinPrep 2000 (Hologic) was uti-
lized for automated processing of all primary ThinPrep collections. The
procedure was executed per manufacturer guidance (11) and without
sodium hypochlorite-based postprocessing decontamination protocols
devoted to each processing event. Cytotechnologists did not change gloves
each time a new ThinPrep vial was introduced to the ThinPrep 2000.
GAA treatment of primary ThinPrep collections. A protocol de-
rived from previous reports (8, 12) was validated for GAA treatment of
ThinPrep collections initially observed to contain excessive erythrocytes,
cervical mucus, acute inflammatory cells, or cytological debris. In brief,
residual ThinPrep contents were treated for 2min with 3ml concentrated
GAA. Final specimen volumewas adjusted to 50ml with CytoLyt solution
(Hologic). Upon centrifugation, pelleted material was resuspended in 5
ml CytoLyt prior to automated reprocessing.
Aptima HPV. For analysis by Aptima HPV on the Tigris DTS system,
1-ml ThinPrep aliquots were dispensed into tubes containing lysis me-
dium. Paradigms of oligonucleotide-specific target capture, TMA, and
hybridization protection (13) were utilized to generate a luminescence-
based result. The assay detects E6/E7mRNA fromhigh-riskHPV types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Internal control
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material (provided within assay reagents and subjected to the samemeth-
odology as specimen aliquots) was used to assess the presence of endoge-
nous specimen inhibitors, with these data expressed as relative light units
(RLU). An analyte signal-to-cutoff ratio (s/co) represented the relation-
ship between the specimen RLU value and a calibrator-derived analyte
cutoff value. An s/co of0.50 denoted a positive result.
Cervista. Two-milliliter ThinPrep aliquots were subjected to a previ-
ously described paramagnetic-based DNA extraction and HPV-specific
Invader-based hybridization (14). In brief, luminescence-labeled oligo-
nucleotides specific for DNA of high-risk HPV types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66, and 68 were incubated with DNA extracts for 4 h
at 62°C. Relative genomic DNA (gDNA) content was assessed by a lumi-
nescence-labeled human histone-specific oligonucleotide and was subse-
quently expressed as a ratio to background luminescence. gDNA-specific
luminescence equaling or exceeding a 1.50 ratio to background consti-
tuted sufficient DNA extraction for a valid patient result. HPV-specific
luminescence from a given oligonucleotidemixture was required to equal
or exceed a 1.525 ratio to background for a positive result.
Assessment of carryover potential relative to automation. Ninety-
two tandem pairs of ThinPrep vials, constituting both a positive and neg-
ative result via previous clinical Cervista performance, were subjected to
Aptima HPV both before (preprocessing aliquot) and after ThinPrep
2000 processing (postprocessing aliquot) (Fig. 1). Pre- and postprocess-
ing aliquots of a given specimen were analyzed in the same batch for
Aptima HPV testing. Operation of the automated cytology processor was
shared within a pool of four cytotechnologists. Forty randomly selected
ThinPrep vials were subjected to gDNA content determination by Cerv-
ista both before and after cytology processing.
Determination of GAA effect on Aptima HPV. Residual material
from236ThinPrep vials deemedunsatisfactory for initial cytology screen-
ing was forwarded for tandemAptima HPV and Cervista analyses follow-
ing treatment by GAA (Fig. 2). In brief, an3.5-ml aliquot of ThinPrep
contents was removed for subsequent molecular HPV screening (mock
treatment). The remainder of theThinPrep collectionwas subjected to the
aforementioned GAA treatment protocol. Aliquots (GAA treatment)
were then delivered to the Aptima HPV and Cervista testing systems,
along with appropriate aliquot volumes of the correspondingmock treat-
ment. GAA andmock treatments of a given specimenwere analyzed in the
same batch for Aptima HPV and Cervista testing.
Data analysis. The significance test of proportions was used to deter-
mine if differences in result distributions were significant. Kappa and
agreement statistics were calculated with respect to results generated with
and without GAA treatment. The t test for independent samples was used
to determine if differences in luminescent data were significant between
treatment groups. The alpha level was set at 0.05 before the investigations
commenced, and all P values are two-tailed.
RESULTS
Characterization of antecedent Cervista-positive and -negative
ThinPrep contents by Aptima HPV. Eighty-nine (96.7%) of 92
preselected Cervista-positive or -negative ThinPrep vials gener-
ated expected results when a preprocessing aliquot was subjected
to AptimaHPV (Fig. 3A). The same concordance rate was derived
from Aptima HPV analysis of aliquots of the ThinPrep study set
following automated cytology processing (Fig. 3B).
One specimen yielded positive Aptima HPV results from both
preprocessing and postprocessing aliquots of the antecedent Cerv-
ista-negative ThinPrep vial. An additional two specimens generated
negative AptimaHPV results when the expected antecedent Cervista
resultswerepositive.As such, these three tandempairswere excluded
from automated cytology processing carryover analysis.
Effect of automated cytology processing on subsequent Ap-
tima HPV performance. Forty randomly selected ThinPrep vials
FIG 1 Experimentation to assess the effect of automated cytology processor
carryover potential on Aptima HPV performance.
FIG 2 Experimentation to assess effects of glacial acetic acid (GAA) treatment
of ThinPrep vials on Cervista and Aptima HPV performance.
FIG 3 Results from Aptima HPV assessment of preprocessing (A) and
postprocessing (B) aliquots of 92 preselected Cervista-positive and -nega-
tive ThinPrep vials.
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yielded equivalent gDNA results via Cervista before and after re-
processing (P  0.41) (Table 1), suggesting that reprocessing
would not bias a postprocessingAptimaHPV result on the basis of
insufficient amounts of nucleic acid. When results were stratified
by individual cytotechnologists, no significant differences in pre-
and postprocessing gDNA content were observed (P 0.15) (data
not illustrated). When tested by Aptima HPV, all 45 evaluable
negative postprocessing aliquots retained a negative result, and
97.7% of 44 evaluable positive postprocessing aliquots retained a
positive result.
Effect of GAA on Aptima HPV. Of 236 prospective ThinPrep
vials requiring GAA treatment, 37 were initially positive via Ap-
tima HPV, while 41 were initially positive via Cervista. Less than
1% of all Aptima HPV results varied upon GAA treatment (Table
2), while 8.5% of initial Cervista results changed under similar
circumstances (P 0.0002). Just 2.7% of initially positive Aptima
HPV results failed to retain this status following GAA treatment,
whereas 21.9%of initially positive specimens via Cervista reverted
to a negative result uponGAA treatment (P 0.01). AptimaHPV
measures related to high-risk HPV RNA detection (s/co) and in-
hibitor assessment (internal control RLU) did not vary post-GAA
treatment (P  0.07) (Table 3). In contrast, gDNA content (as
measured by Cervista) was significantly reduced following GAA
treatment (Table 2).
DISCUSSION
Laboratories exploring automation prospects for both ThinPrep
vial processing and molecular HPV performance have been con-
fronted with recommendations for meticulous decontamination
of such instrumentation, particularly with respect to automated
cytology processors. Past package insert material for delivery of
processed ThinPrep contents to specimen aliquot tubes for Ap-
tima HPV (7) has described an in-house-validated procedure to
mitigate the potential for cross-contamination during ThinPrep
2000 processing. Two important components of this procedure
included (i) soaking the filter cap in 0.5% sodium hypochlorite
solution for 1 min between samples and (ii) mandating that the
operator change gloves between each sample.
When these recommendations first surfaced, alternative strat-
egies for primary specimen processing were entertained by labo-
ratories dealing with significant cytology and/or HPV testing
volume. Prealiquoting for HPV screening from a cytology speci-
men with low cellularity could further reduce volume or render
the specimen unusable for assessment by cytological analysis.
Furthermore, aliquoting of every specimen for HPV screening
may not be necessary if the cytology result yields a result other
than ASC-US (15). This strategy could also be limited by fiscal,
staffing, and consumable storage considerations. Some of these
ancillary factors could also influence the decision of a laboratory
to implement strict decontamination practices surrounding each
ThinPrep input through an automated processor. Moreover,
turnaround time to final HPV screening result would be predi-
cated based on the length of time necessary for initial cytology
processing.
A final alternative strategy entails extensive verification of a
routine automated cytology processing protocol (as described in
Materials andMethods), with subsequent Aptima HPV screening
designated a laboratory-modified test (16). When this study was
initiated, Cervista was the HPV screening modality employed by
our laboratory. As such, when we attempted to preselect positive
and negative specimens for a carryover analysis investigation (Fig.
1), the possibility existed for discordance between theCervista and
Aptima HPV data. Explanations for this have ranged from in-
creased sensitivity of TMA-based testing versus that of DNA hy-
bridization (17) to a recent characterization of false-positive re-
sults inherent to Cervista (5). Furthermore, specimens may have
containedDNAor RNA, but not both. Indeed, three tandempairs
of data were excluded from analysis (Fig. 3B) because two initially
positive Cervista results did not translate into positive Aptima
HPV results, while one initially negative Cervista specimen was
Aptima HPV positive.
TABLE 1 Cervista-derived gDNA assessment of 40 ThinPrep vial
aliquots prior to and following automated cytology processing
Cervista result n
Mean gDNA content in:
P
Preprocessing
aliquot
Postprocessing
aliquot
Positive 20 15.877 13.774 0.22
Negative 20 13.728 14.017 0.84
Cumulative 40 14.802 13.896 0.41
TABLE 2 Summary of intra-assay comparisons of Cervista and Aptima HPV prior to and following glacial acetic acid treatment of 236 specimens
Result parameter
Results (%) for:
P Agreement (95% CI)a Kappa (95% CI)Cervista Aptima HPV
Remain positive following GAA
treatment
78.1 97.3 0.01 0.903 (0.731–0.975) 0.367 (0–0.894)
Remain negative following
GAA treatment
95.8 99.5 0.02 0.963 (0.922–0.984) 0.215 (0–0.568)
Mock,b GAA treatment result
concordance
91.5 99.2 0.0002 0.955 (0.916–0.977) 0.274 (0–0.577)
a CI, confidence interval.
b No treatment with glacial acetic acid.
TABLE 3 Data output specific to Cervista and Aptima HPV assays with
respect to mock and glacial acetic acid treatment of 236 ThinPrep
specimens
Background parameter
Mean data for:
P
Mock
treatment
GAA
treatment
Cervista gDNA content 11.05 9.27 0.0015
Aptima HPV signal/cutoff 1.881 1.673 0.64
Aptima HPV internal
control value
218,394 227,264 0.07
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As a result, 89 tandem sets of antecedent Cervista-positive and
-negative ThinPrep vials were evaluated for carryover. The mean
HPV-specific luminescence-to-background ratio of the HPV-
positive vials (5.209) was approximately 240% greater than the
cutoff value required for a positive result (data not illustrated).
The aforementioned 96.7% concordance rate between Aptima
HPV/Cervista results in the carryover portion of this investigation
was higher than the 88.7% concordance rate between the two
assays previously described in a study set of 4,056 specimens (5).
In addition to the smaller study set utilized in the current investi-
gation, preselection of (Cervista) stronglyHPV-positive ThinPrep
vials would inherently lend itself to a higher concordance rate than
would a prospective analysis.
In spite of the strongly HPV-positive ThinPrep vial directly
preceding a negative ThinPrep vial during cytology reprocessing,
the subsequent performance of Aptima HPV did not result in
reversion of expected negative results to positive. These observa-
tions imply that carryover risk ascribed to the ThinPrep 2000 is
negligible in the context of TMA-based HPV screening. More-
over, the high rate of concordance experienced in Aptima HPV
performance of the preprocessing aliquots (Fig. 3A), apart from
analytical variance related to the Cervista assay, suggests that the
risk for cross-contamination related to the Tigris DTS itself is also
very minimal. Chernesky et al. (18) reported98% agreement of
Aptima Combo 2 (Hologic/Gen-Probe) Chlamydia trachomatis
results in precytology and postcytology fractions of 394 SurePath
(BD Diagnostics-TriPath, Burlington, NC) collections. The data
in our study not only were generated on the basis of a different
microbe and an alternative liquid-based cytology medium but
also were assessed with an automated platform for nucleic acid
amplification testing and an automated means of cytology pro-
cessing. Similar findings are reported.
We previously demonstrated that Cervista is greatly affected by
GAA treatment (10). Analysis of 465 specimens revealed signifi-
cant decreases in gDNA content and rates of positive HPV results
upon GAA treatment. This effect was independently documented
for two divergent GAA treatment protocols. These findings were
consistent with a less-rigorous study (9) but were a departure
from those of another report describing no deleterious effects of
GAA (8). To our knowledge, one assessment of GAA effect on
Aptima HPV has been reported. Dockter et al. (19) added known
concentrations of GAA to ThinPrep contents and demonstrated
negligible effects on Aptima HPV. In our report, we present a
second large independent data set to confirm the deleterious ef-
fects of GAA on Cervista. Furthermore, a prospectively designed
investigation of primary ThinPrep specimens directly demon-
strated less of an effect of GAA treatment on AptimaHPV than on
Cervista (Table 2). Whereas the gDNA content of Cervista was
significantly affected byGAA treatment, GAAdid not significantly
affect parameters associatedwithmRNA-basedAptimaHPV (P
0.07) (Table 3). Additional studiesmay bewarranted to determine
if RNA is less susceptible to the effect of GAA or if the target
capture system inherent toAptima assays plays a role inmitigating
the potentially deleterious effect of this treatment.
In conclusion, specimen carryover emanating from the func-
tion of an automated cytology processor was not evident upon the
subsequent performance of Aptima HPV. Although past guide-
lines for meticulous decontamination protocols have recently
been superseded by internal manufacturer studies and package
insert revisions (20), protocols described in this report can prove
useful to cytopathologists and molecular diagnosticians in the
context of quality assurance programs. In particular, the sche-
matic illustrated in Fig. 1 can address College of American Pathol-
ogists Accreditation Program standards, such as checklist require-
ment MOL.34875, which deal with carryover in the molecular
diagnostics laboratory (21). GAA treatment of ThinPrep vials has
less deleterious effects on Aptima HPV performance than on
Cervista. Taken together, preanalytical factors are ofminimal con-
cern with respect to Aptima HPV performance, ultimately allow-
ing for appropriate contributions of adjunctive HPV screening
data to overall cervical cancer triage.
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